Research and Markets: 2007 Trial TRAX – Alzheimer’s Disease – Clinical Trial Monitoring Brief Provides Detailed Compilations And Analysis Of Ongoing Studies

Research and Markets (http://www.researchandmarkets.com/reports/c70521) has announced the addition of Trial TRAX – Alzheimer’s Disease – Clinical Trial Monitoring Brief to their offering.

The main body of the brief presents key data points from competitor clinical trials in a matrix format, enabling decision-makers the ability to quickly recall and analyze information on competitor studies. The brief’s reference-guide format is designed to provide decision makers with easy access to key intelligence on competitive clinical development programs. Primary data points include:

– Study Drug

– Mechanism of Action

– Company-Sponsor

– Phase of Development

– Number of Patients

– Study Design

– Primary Endpoints

– Study Start Date

Clients utilize the Trial TRAX briefing reports to:

– Monitor clinical development programs of competitors

– Quickly evaluate depth and breadth of competitive landscape

– Easy-to-use reference guide for analyzing competitor clinical trials

– Identify potential patient recruitment challenges

– Benchmark competitor clinical trial designs

The Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on the profiled-disease; typically includes top-line information on:

– Epidemiology

– Patient Segmentation

– Clinical endpoints

The Trial TRAX brief also contains analysis of the clinical landscape with assessments including:

– % utilization of key clinical endpoints

– Number of ongoing trials (by phase of development)

– Key companies sponsoring clinical trials

Content Outline:

Section 1: Executive Summary

Alzheimer’s Disease Overview: Background, Epidemiology

Alzheimer’s Disease Overview: Etiology & Disease Staging

Treatments for Alzheimer’s Disease

Historical Sales of Market Alzheimer’s Disease Therapeutics

Clinical Endpoints in Alzheimer’s Disease Trials

Overview of Clinical Landscape

Key Players in Alzheimer’s Disease

Section 2: Ongoing Clinical Trial in Alzheimer’s Disease

Competitive Clinical Trial Details

Section 3: Appendix

Disclaimer

Report Licensing

Companies Mentioned:

– Eli Lilly

– GlaxoSmithKline

– Merck

– Novartis

– Pfizer

– Wyeth

For more information visit http://www.researchandmarkets.com/reports/c70521.